Poly (ADP-ribose) polymerase inhibitor: An evolving paradigm in the treatment of prostate cancer

Asian Journal of Andrology

Volumn 16, Issue 3, 2014, Pages 401-406

  Zhang, Jingsong ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Biomarker; PARP inhibitor; Prostate cancer; Therapy

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ENZALUTAMIDE; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RAD51 PROTEIN; RADIUM CHLORIDE RA 223; TEMOZOLOMIDE; VELIPARIB; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PTEN PROTEIN, HUMAN; RAD51 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR ETS;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; GENE MUTATION; GENE REARRANGEMENT; HUMAN; PROSTATE CANCER; REVIEW; TRANSCRIPTION REGULATION; ANOXIA; ANTAGONISTS AND INHIBITORS; GENETICS; MALE; METABOLISM; MULTIMODALITY CANCER THERAPY; MUTATION; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; ANOXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA2 PROTEIN; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; HUMANS; MALE; MUTATION; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-ETS; PTEN PHOSPHOHYDROLASE; RAD51 RECOMBINASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84900499492     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.123684     Document Type: Review

References (53)

1. Ohnishi T, Mori E, Takahashi A. DNA double-strand breaks: Their production, recognition, and repair in eukaryotes. Mutat Res 2009; 669: 8-12
2. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, et al. Review of the Lynch syndrome: History, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009; 76: 1-18
3. Lynch HT, Silva E, Snyder C, Lynch JF. Hereditary breast cancer: Part I. Diagnosing hereditary breast cancer syndromes. Breast J 2008; 14: 3-13
4. Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, et al. Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009; 3: 97-137
5. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8: 193-204
6. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481: 287-94
7. Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly (ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 2011; 61: 31-49
8. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-74
9. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22
10. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448: 595-9
11. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-43
12. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, et al. Punctuated evolution of prostate cancer genomes. Cell 2013; 153: 666-77
13. Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, et al. Defects of DNA mismatch repair in human prostate cancer. Cancer Res 2001; 61: 4112-21
14. Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA, et al. Defective DNA strand break repair after DNA damage in prostate cancer cells: Implications for genetic instability and prostate cancer progression. Cancer Res 2004; 64: 8526-33
15. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685-9
16. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, et al. Mechanistic rationale for inhibition of poly (ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011; 19: 664-78
17. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 315-22
18. Liu JJ, Zhang J. Sequencing systemic therapies in metastatic castration-resistant prostate cancer. Cancer Control 2013; 20: 181-7
19. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
20. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97
21. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-48
22. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22
23. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: Randomised open-label trial. Lance 2010; 376: 1147-54
24. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-23
25. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8: 180-92
26. Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013; 31: 1748-57
27. Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012; 2: 1134-49
28. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34
29. Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 2010; 11: 196-207
30. Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, et al. PTEN Deletion in Prostate Cancer Cells Does Not Associate With Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy. Clin Cancer Res 2011; 18: 1015-27
31. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, et al. The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: Phase 1 dose-escalation trial. Lancet Oncol 2013; 14: 882-92
32. Klein HL. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst) 2008; 7: 686-93
33. Arias-Lopez C, Lazaro-Trueba I, Kerr P, Lord CJ, Dexter T, et al. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep 2006; 7: 219-24
34. Fong V, Osterbur M, Capella C, Kim YE, Hine C, et al. Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells. PloS ONE 2011; 6: E28714
35. Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PloS ONE 2010; 5: E11208
36. Brown ET, Holt JT. Rad51 overexpression rescues radiation resistance in BRCA2-defective cancer cells. Mol Carcinog 2009; 48: 105-9
37. Yang Z, Waldman AS, Wyatt MD. Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. Biochem Pharmacol 2012; 83: 741-6
38. Lee SA, Roques C, Magwood AC, Masson JY, Baker MD. Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-Type Rad51 expression. DNA Repair (Amst) 2009; 8: 170-81
39. Martin RW, Orelli BJ, Yamazoe M, Minn AJ, Takeda S, et al. RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res 2007; 67: 9658-65
40. Marignol L, Coffey M, Lawler M, Hollywood D. Hypoxia in prostate cancer: Powerful shield against tumour destruction̈ Cancer Treat Rev 2008; 34: 313-27
41. Bindra RS, Schaffer PJ, Meng A, Woo J, Maseide K, et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 2004; 24: 8504-18
42. Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 2005; 76: 168-76
43. Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 2010; 70: 8045-54
44. Papp-Szab E, Josephy PD, Coomber BL. Microenvironmental influences on mutagenesis in mammary epithelial cells Int J Cancer 2005; 116: 679-85
45. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996; 56: 5754-7
46. Krishnakumar R, Kraus WL. The PARP side of the nucleus: Molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010; 39: 8-24
47. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, et al. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728-37
48. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in Diverse tumors. Clin Cancer Res 2009; 15: 7277-90
49. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005; 65: 6394-400
50. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013; 19: 3621-30
51. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 6: 487-95
52. Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013; 15: 1-10
53. Chatterjee P, Choudhary GS, Sharma A, Singh K, Heston WD, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE 2013; 8: E60408.